Literature DB >> 3598159

Immune effects of alpha-interferon in chronic liver disease.

M Peters, D M Walling, J Waggoner, M I Avigan, M Sjogren, J H Hoofnagle.   

Abstract

The effect of prolonged alpha-interferon therapy on immune function was studied in patients with chronic type B hepatitis. These patients with chronic type B hepatitis have been shown to have a defect in their in vitro response to human recombinant alpha-interferon. This defect consists of a failure to augment pokeweed mitogen-stimulated immunoglobulin production at low concentrations of interferon and an increased susceptibility to the suppressive effects of interferon. After 2 weeks therapy with interferon, immunoglobulin production was further suppressed. However, after 4 months of therapy with interferon, pokeweed mitogen-stimulated immunoglobulin production partially returned towards the pretreatment values. Antibody to hepatitis B core antigen was less affected by interferon therapy. This altered response to interferon was not specific as it was seen in some patients with other forms of liver disease. The suppression of B cell differentiation appears to be separate from its antiviral and antiproliferative effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3598159     DOI: 10.1016/s0168-8278(86)80133-7

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

Review 1.  Immunological aspects of antiviral therapy.

Authors:  M Peters
Journal:  Springer Semin Immunopathol       Date:  1990

2.  Effects of recombinant leukocyte interferon on serum immunoglobulin concentrations and lymphocyte subpopulations in chronic hepatitis B.

Authors:  H Tsuji; K Murai; K Akagi; M Fujishima
Journal:  J Clin Immunol       Date:  1990-01       Impact factor: 8.317

3.  Efficacy of pegylated interferon α2a in patients without HBeAg loss after the withdrawal of long-term lamivudine therapy.

Authors:  Xu-Qing Zhang; Hui-Yan Zhang; Jian-Ping You; Qing Mao
Journal:  Virol J       Date:  2013-01-15       Impact factor: 4.099

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.